Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mistelbach – page 8

889 clinical trials in Mistelbach, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mistelbach at a glance
889
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

889 trials in Mistelbach

Open in trial search

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RO7589655
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Myopia

Recruiting

Safety and Efficacy of Sodium Phenylbutyrate Eye Drops in Children with Myopia

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Sodium Phenylbutyrate
  • Sponsor:Laboratoires Thea

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Belatacept Dose Reduction Safety in Kidney Transplant Recipients with a Well-Matched Donor

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Belatacept
  • Sponsor:Medical University Of Vienna

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Deciphera Pharmaceuticals Inc.

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mistelbach

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on stroke prevention and management of atrial fibrillation. Research evaluates innovative treatments comparing asundexian to established medications for reducing stroke risk in patients with irregular heartbeat.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Systemic Embolism Prevention

Trials aim to assess both effectiveness and safety profiles of new therapeutic approaches.

02 Oncology Studies

Advanced research in breast cancer treatment, specifically focusing on hormone receptor-positive/HER2-negative early breast cancer. Studies evaluate the effectiveness of combining palbociclib with standard endocrine therapy.

  • Early Breast Cancer Treatment
  • Endocrine Therapy Enhancement
  • Disease-Free Survival Assessment

Research aims to improve treatment outcomes through innovative combination therapies.

03 Neurology Research

Innovative studies examining treatments for acute ischemic stroke and high-risk transient ischemic attacks. Research evaluates the efficacy of milvexian in reducing stroke risk compared to placebo.

  • Acute Stroke Treatment
  • Ischemic Attack Prevention
  • Neurological Recovery

Focus on developing more effective interventions for stroke prevention and management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.